Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · IEX Real-Time Price · USD
3.765
+0.045 (1.21%)
At close: Jul 19, 2024, 4:00 PM
3.790
+0.025 (0.66%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Sutro Biopharma Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Sutro Biopharma stock have an average target of 12.5, with a low estimate of 8.00 and a high estimate of 18. The average target predicts an increase of 232.01% from the current stock price of 3.77.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 15, 2024.
Analyst Ratings
The average analyst rating for STRO stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $10 | Buy | Maintains | $10 | +165.60% | May 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +218.73% | May 14, 2024 |
| Wedbush | Wedbush | Buy Reiterates $8 | Buy | Reiterates | $8 | +112.48% | May 14, 2024 |
| B of A Securities | B of A Securities | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +218.73% | May 8, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $17 | Buy | Reiterates | $17 | +351.53% | Apr 3, 2024 |
Financial Forecast
Revenue This Year
57.37M
from 153.73M
Decreased by -62.68%
Revenue Next Year
45.80M
from 57.37M
Decreased by -20.15%
EPS This Year
-3.53
from -1.78
EPS Next Year
-3.64
from -3.53
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 109.2M | 66.9M | 77.3M | 697.2M | 930.3M |
| Avg | 57.4M | 45.8M | 59.7M | 185.3M | 318.8M |
| Low | 27.4M | n/a | 39.2M | 23.3M | 67.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -29.0% | 16.6% | 68.7% | 1,068.7% | 402.1% |
| Avg | -62.7% | -20.2% | 30.2% | 210.6% | 72.0% |
| Low | -82.2% | - | -14.4% | -60.9% | -63.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.56 | -2.11 | -2.24 | -3.19 | -3.15 |
| Avg | -3.53 | -3.64 | -3.53 | -3.10 | -3.06 |
| Low | -4.02 | -4.76 | -4.66 | -2.98 | -2.94 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.